Company intelligence
Oragenics, Inc
We are developing medical technologies that solve unmet clinical needs and have a substantial market opportunity.
Biotechnology
Tampa, US
18 employees
3 public signals
About Oragenics, Inc
Every year, 69 million people worldwide sustain a concussion. Not one has access to an FDA-approved pharmacological treatment. Oragenics is a development-stage biopharmaceutical company on a mission to change that. We are developing the first-ever pharmacological treatment for acute concussion — a first-in-class intranasal neurosteroid with a clear FDA regulatory pathway and intellectual property protection through 2040+.
Verified activity
Signals from Oragenics, Inc
3 published signals
Research & Knowledge
Oragenics, Inc is developing ONP-002 for concussion and mTBI with patients now dosing in a Phase IIa trial.
Reported by Oragenics, Inc
Research & Knowledge
Oragenics, Inc is advancing ONP-002 through clinical development for concussion and mTBI.
Reported by Oragenics, Inc
Research & Knowledge
Oragenics, Inc is currently in clinical trials for ONP-002, an investigational therapy utilizing a proprietary intranasal delivery platform to explore solutions for mTBI and neuroprotection in vulnerable populations.
Reported by Oragenics, Inc